证券代码：301126 证券简称：达嘉维康 公告编号：2025-030 湖南达嘉维康医药产业股份有限公司 关于召开 2024 年年度股东大会的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合《中华人民 共和国公司法》、《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 （2）网络投票时间：2025 年 5 月 12 日（星期一） 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 12 日 9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投 票系统投票的具体时间为：2025 年 5 月 12 日 9:15—15:00 期间的任意时间。 5、会议的召开方式：采取现场投票与网络投票相结合的方式召开。公司将 同时通过深圳证券交易所交易系统和互联网投票系统（http://wltp ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-020 湖南达嘉维康医药产业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届监事会第十 一次会议于 2025 年 4 月 17 日在公司会议室以现场结合通讯的方式召开。会议通 知已于 2025 年 4 月 7 日通过邮件、电话、微信等方式送达全体监事。本次会议 应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席唐娟女士召集并主 持。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等有关法 律、法规及规范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： （一）审议通过《关于<2024 年度监事会工作报告>的议案》 2024 年度，公司监事会按照《公司法》、《证券法》等法律法规以及《公 司章程》、《监事会议事规则》等有关规定的要求，对公司股东大会和董事会等 会议的召集召开程序、公司经营活动、财务状况、重大决策 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-019 湖南达嘉维康医药产业股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）审议通过《关于<2024 年度董事会工作报告>的议案》 2024 年，公司董事会严格按照《公司法》、《证券法》等法律法规以及《公 司章程》、《董事会议事规则》等有关规定的要求，认真贯彻执行股东大会通过 的各项决议，勤勉尽责，较好地履行了公司及股东赋予董事会的各项职责。 1 一、董事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届董事会第十 四次会议于 2025 年 4 月 17 日在公司会议室以现场结合通讯的方式召开。会议 通知已于 2025 年 4 月 7 日通过邮件、电话、微信等方式送达各位董事。本次会 议应出席董事 7 人，实际出席董事 7 人。本次会议由董事长王毅清先生召集并 主持，公司监事、高级管理人员列席了本次会议。本次会议的召集、召开和表 决程序符合《中华人民共和国公司法》等法律、法规及规范性文件和《公司章 程》的有关规定。 二、 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-025 湖南达嘉维康医药产业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2024 年度利润分配预案为：以公司 2024 年 12 月 31 日的总股本 205,403,200 股为基数向全体股东每 10 股派发现金 0.818 元人民币（含税），共 计派发现金 16,801,981.76 元（含税），剩余未分配利润结转至下一年。 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第四届董事会第十四次会议和第四届监事会第十一次会议，审议通过 了《关于 2024 年度利润分配预案的议案》。 1、董事会审议程序 公司第四届监事会第十一次会议审议通过了《关于 2024 年度利润分配预案 的议案》，监事会认为，公司 2024 年度利润分配方案符合公司的实际情况， ...

Financial Performance - The company's operating revenue for 2024 reached ¥5,233,420,808.02, representing a 34.07% increase compared to ¥3,903,503,781.52 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥26,574,897.24, a decrease of 22.52% from ¥34,299,844.15 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥25,606,109.23, down 25.40% from ¥34,322,553.37 in 2023[17]. - The total assets at the end of 2024 amounted to ¥6,178,190,385.57, an increase of 17.06% from ¥5,277,655,319.75 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.13, a decline of 23.53% compared to ¥0.17 in 2023[17]. - The weighted average return on equity for 2024 was 1.52%, down from 1.98% in 2023[17]. - The net cash flow from operating activities for 2024 was ¥24,041,119.19, a decrease of 11.39% from ¥27,130,076.95 in 2023[17]. - The company reported a net profit of ¥4,616,350.00 in Q3 2024, significantly lower than the profit of ¥12,397,081.78 in Q2 2024[19]. - The company achieved a total revenue of ¥5,233,420,808.02 in 2024, representing a year-on-year growth of 34.07%[48]. - Net profit for 2024 reached ¥51,330,200, marking a 35.05% increase compared to the previous year[48]. Dividend Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 0.818 RMB per 10 shares, based on a total of 205,403,200 shares[5]. - The company plans to distribute a cash dividend of RMB 0.818 per 10 shares, totaling RMB 16,801,981.76 for the year 2024[158]. - The total distributable profit for the company as of December 31, 2024, is RMB 561,184,256.91, with the mother company having a distributable profit of RMB 56,072,544.43[157]. - The company will not issue new shares or convert capital reserves into share capital in the 2024 profit distribution plan[158]. - The company has a clear and transparent cash dividend policy, complying with relevant regulations and ensuring shareholder rights are protected[153]. Market Expansion and Strategy - The company plans to expand its market presence and enhance its product offerings through new technologies and research initiatives[11]. - The management discusses potential strategies for mergers and acquisitions to strengthen market position[11]. - The company is focusing on digital transformation and the integration of online and offline services to enhance its healthcare ecosystem[33]. - The company is actively expanding into the upstream pharmaceutical industry and enhancing its retail pharmacy resources[33]. - The company aims to enhance its R&D capabilities through increased investment and collaboration between its pharmaceutical distribution and industrial businesses[41]. - The company is focusing on developing an "Internet +" prescription drug retail model, expanding sales channels through collaborations with various apps and third-party e-commerce platforms, and building a shared platform for prescription flow between hospitals and pharmacies[96]. - The company aims to enhance its brand influence and market competitiveness through a comprehensive integration of its pharmaceutical distribution and manufacturing operations[48]. - The company is addressing the risk of regional business concentration by establishing subsidiaries in regions like Ningxia and Hainan, employing a "new build + acquisition + franchise" strategy for national expansion[99]. Research and Development - R&D expenses rose by 126.64% to ¥16,257,767.71, mainly driven by increased drug development costs in the industrial sector[56]. - The number of R&D personnel increased by 89.47% from 19 to 36, enhancing the company's R&D capacity[59]. - R&D investment for 2024 is ¥16,257,767.71, which is 0.31% of operating revenue, up from 0.18% in 2023[59]. - The company has five new R&D projects, including studies on Norfloxacin capsules and raw materials, aimed at expanding its product portfolio[59]. - The company is increasing R&D investment in traditional Chinese medicine and innovative drugs, aiming to enhance product quality and market competitiveness through technological upgrades[97]. Corporate Governance - The company has an independent financial accounting system and does not share bank accounts with the controlling shareholder, maintaining financial independence[123]. - The board consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[109]. - The company has implemented a performance evaluation and incentive mechanism for directors and senior management, promoting transparency and fairness[111]. - The company has established a robust internal management and control system, enhancing governance and operational efficiency[120]. - The company has actively improved its information disclosure practices, ensuring equal access to information for all shareholders[112]. Environmental Responsibility - Dajia Weikang adheres to multiple environmental standards, including air and water pollutant discharge standards, such as GB13271-2014 and GB21906-2008[173]. - The company holds a pollution discharge permit valid from February 13, 2023, to February 13, 2028[174]. - The company incurs annual costs of CNY 174,000 for wastewater treatment and CNY 17,000 for hazardous waste disposal[187]. - The company has implemented measures to monitor wastewater and air emissions regularly, ensuring compliance with environmental standards[180][182]. - Dajia Weikang has no recorded administrative penalties related to environmental issues during the reporting period[188]. Employee Management - The total number of employees at the end of the reporting period is 4,887, with 3,080 from major subsidiaries[146]. - The salary policy is based on a combination of ability and contribution, with total salary determined by annual budget and market conditions[148]. - Employee performance pay is directly linked to individual performance output and overall unit performance[148]. - The company provides statutory benefits including pension, medical, unemployment, work injury, maternity insurance, and housing fund[148]. - The company has established a wide salary system based on job levels to enhance employee motivation and efficiency[148]. Financial Management - The company has pledged assets totaling ¥425,941,689.19, including cash and fixed assets, for various loans and guarantees[70]. - The company reported a significant decrease in investment income, with a loss of ¥377,184.75, accounting for -0.50% of total profit[63]. - The company has utilized ¥54,367.87 million of the raised funds, representing 95.47% of the total raised amount[80]. - The company plans to use 1,700 million yuan of the raised funds to permanently supplement working capital[84]. - The company will focus on implementing investment projects from the raised funds to quickly achieve expected benefits, aligning with industry development trends and overall strategic direction[199].

Financial Performance - The company's revenue for Q1 2025 was CNY 1,299,820,581.67, representing a 1.51% increase compared to CNY 1,280,469,171.09 in the same period last year[5] - Net profit attributable to shareholders decreased by 83.82% to CNY 3,144,357.36 from CNY 19,436,945.89 year-on-year[5] - The diluted earnings per share decreased by 77.78% to CNY 0.02 from CNY 0.09 in the same period last year[5] - Net profit for the current period was ¥10,626,439.28, down from ¥22,059,938.81 in the previous period, indicating a decline of approximately 51.8%[22] - The total comprehensive income attributable to the parent company was ¥3,144,357.36, down from ¥19,436,945.89, a decrease of approximately 83.8%[23] Cash Flow - The net cash flow from operating activities was negative at CNY -201,387,255.36, a decline of 14.76% compared to CNY -175,488,409.39 in the previous year[11] - The net cash flow from investing activities was -$54,606,958.46, indicating a significant outflow compared to the previous period's -$425,988,313.13[25] - The net cash flow from financing activities was $156,977,132.25, a decrease from $338,974,376.99 in the previous period[25] - The ending cash and cash equivalents balance was $421,992,791.70, down from $354,815,404.93, indicating a decline in liquidity[25] - The net increase in cash and cash equivalents was -$99,017,081.57, compared to -$262,502,345.53 in the prior period, showing an improvement in cash management[25] Assets and Liabilities - Total assets increased by 4.29% to CNY 6,443,038,507.14 from CNY 6,178,190,385.57 at the end of the previous year[5] - Current assets amounted to CNY 3,979,298,487.91, up from CNY 3,711,405,478.30 at the start of the period, reflecting a growth of approximately 7.2%[18] - Total liabilities rose to CNY 4,583,840,753.45 from CNY 4,329,490,087.12, indicating an increase of about 5.9%[19] - The company’s long-term borrowings increased significantly to CNY 1,199,788,511.39 from CNY 885,846,727.60, a rise of approximately 35.4%[19] Research and Development - Research and development expenses rose by 50.98% to CNY 3,113,060.00, driven by increased drug development costs in the industrial sector[10] - Research and development expenses increased to ¥3,113,060.00 from ¥2,061,921.04, marking a rise of approximately 50.9%[21] Other Income and Expenses - The company reported a significant increase of 136.30% in other income, totaling CNY 10,241,664.14, due to tax relief from government subsidies for retail chain enterprises[10] - Other income rose to ¥10,241,664.14 from ¥4,334,261.80, reflecting an increase of about 136.5%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,780, with the largest shareholder holding 34.15% of the shares[12] - The minority shareholders' profit increased to ¥7,482,081.92 from ¥2,622,992.92, indicating a growth of approximately 184.5%[23] Company Developments - The company received a drug registration certificate for Oseltamivir Phosphate Granules from the National Medical Products Administration[16] - The company completed the investment project for the "Dajia Weikang Pharmaceutical Industrial Base" and decided to conclude it[16] - The company is actively updating its fundraising documents in response to inquiries from the Shenzhen Stock Exchange[16] Accounting and Audit - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[26] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[27]

2025 年 4 月 3 日，公司和保荐机构国金证券股份有限公司向深圳证券交易 所（以下简称"深交所"）提交了《湖南达嘉维康医药产业股份有限公司关于撤 回 2024 年度向特定对象发行股票并在创业板上市申请文件的申请》和《国金证 券股份有限公司关于撤回湖南达嘉维康医药产业股份有限公司 2024 年度向特定 对象发行股票并在创业板上市申请文件的申请报告》，申请撤回向特定对象发行 股票申请文件。 证券代码：301126 证券简称：达嘉维康 公告编号：2025-018 湖南达嘉维康医药产业股份有限公司 关于收到深圳证券交易所《关于终止对湖南达嘉维康医药产业股份 有限公司申请向特定对象发行股票审核的决定》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日召开第四届董事会第十三次会议、第四届监事会第十次会议，审议通过了《关 于终止向特定对象发行股票事项并撤回申请文件的议案》，同意公司终止本次向 特定对象发行股票事项并撤回申请文件。具体内容详见公司同日在巨潮资讯网 （www.cnin ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301126 证券简称：达嘉维康 公告编号：2025-015 湖南达嘉维康医药产业股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届董事会第十三次会议于2025年4月3日在 公司会议室以现场结合通讯的方式召开。会议通知于2025年3月28日以邮件、电话、微信等方式送达全 体董事。本次会议应出席董事7人，实际出席董事7人。本次会议由董事长王毅清先生召集并主持，公司 监事、高级管理人员列席了本次会议。会议的召集、召开和表决程序符合有关法律、法规、规章和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 1、审议通过《关于终止向特定对象发行股票事项并撤回申请文件的议案》 鉴于目前资本市场环境变化，并结合公司发展战略及经营规划等因素，经相关各方充分沟通、审慎分析 后，公司决定终止本次向特定对象发行股票事项并向深圳证券交易所撤回相关申请文件。 具体内容详 ...

Core Viewpoint - Dajia Weikang has decided to terminate its plan for a private placement of shares and withdraw the application due to the current capital market environment and after thorough communication and analysis among relevant parties [1][4]. Group 1: Termination of Share Issuance - The company held meetings on April 3 to approve the termination of the private placement of shares and the withdrawal of the application [1]. - The planned issuance was intended to raise up to 120 million yuan, with a share price of 7.45 yuan per share, and a maximum of 16,107,382 shares to be issued [1]. - The funds were to be used to supplement working capital after deducting issuance costs [1]. Group 2: Shareholder Information - The intended recipient of the shares was Wang Yiqing, a controlling shareholder and chairman of the company, who was to sign a conditional share subscription agreement [2]. - Wang Yiqing directly holds 70,144,219 shares and indirectly controls an additional 9,800,000 shares, totaling 79,944,219 shares, which is 38.92% of the company's total equity [2]. - Together with his spouse, they control 39.60% of the voting rights in the company [2]. Group 3: Previous Fundraising Efforts - Dajia Weikang was listed on the Shenzhen Stock Exchange on December 7, 2021, raising 639 million yuan, with a net amount of 569 million yuan after expenses [3]. - The funds from the initial public offering were intended for chain pharmacy expansion, smart logistics center projects, and repaying bank loans [3]. - The company had previously announced the termination of a simplified procedure for a private placement in 2022, which aimed to raise up to 199.12 million yuan for acquisitions and working capital [5].

证券代码：301126 证券简称：达嘉维康 公告编号：2025-016 湖南达嘉维康医药产业股份有限公司 一、监事会会议召开情况 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 4 月 3 日以现场结合通讯的方式召开。会议通知于 2025 年 3 月 28 日以邮件、电话、微信等方式送达全体监事。本次会议应出席监事 3 人， 实际出席监事 3 人。本次会议由监事会主席唐娟女士召集并主持。会议的召集、 召开和表决程序符合有关法律、法规、规章和《公司章程》的规定。 二、监事会会议审议情况 表决结果：3 票同意，0 票反对，0 票弃权。 三、备查文件 特此公告。 湖南达嘉维康医药产业股份有限公司监事会 经与会监事认真审议，形成以下决议： 经审议，监事会认为公司本次终止向特定对象发行股票事项并撤回申请文件 不会对公司正常生产经营造成重大不利影响，不存在损害公司及全体股东，特别 是中小股东利益的情形。监事会同意公司终止向特定对象发行股票事项并撤回申 请文件。 具体内容详见公司同 ...